Ajanta Pharma Q2FY27 EBITDA Rises 47% Year Over Year
Prabhudas Lilladher reports EBITDA of INR 5.43bn and a 30.2% operating margin, above its estimates. It attributes the increase to higher revenue across branded generic markets.
Prabhudas Lilladher's research report on Ajanta PharmaAJP’s Q2FY27 EBITDA grew strongly by 47% YoY (INR 5.43bn; 30.2% OPM) which was sharply above our estimates. The beat was aided by higher revenues across branded generic markets. The recent in-licensing agreement with Biocon for marketing semaglu…